Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

Business Leaders

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
HomeAll NewsMost read newsBusiness Leaders Biography
Portrait de John Tsai
Age : 53
Public asset : 7,266,654 USD
Country of residence : Unknown
Linked companies : Novartis AG

Biography of John Tsai 
Presently, John Tsai is Chief Medical Officer at Novartis AG. In his past career Dr. Tsai was Chief Medical Officer & SVP-Global Medical at Amgen, Inc. and Head-Clinical Development at Bristol Myers Squibb Co. He received a doctorate from the University of Louisville School of Medicine and an undergraduate degree from Washington University in St. Louis.


Current positions of John Tsai 
Holdings of John Tsai 
John Tsai : Personal Network 
Most Read News 
01:26pJACK DORSEY : Twitter's Dorsey leads $29 billion buyout of lending pioneer Afterpay
RE
07/28MARK ZUCKERBERG : Facebook's slowdown warning hangs over strong ad sales, while Zuckerberg talks 'metaverse'
RE
07/20JEFF BEZOS : billionaire Bezos has successful suborbital jaunt
RE
07/26JEFF BEZOS : Bezos-backed plant food firm NotCo joins unicorn club after latest funding
RE
07/26MICHAEL KLEIN : EV maker Lucid rises in Nasdaq debut after merger with Klein-backed SPAC
RE
07/27RAJESH KUMAR : GE warns of inflationary pressure after lifting cash flow estimate
RE
07/26JEFF BEZOS : Bezos offers NASA $2 billion in exchange for moon mission contract
RE
07/27IAN READ : Exclusive-Rivian ready to invest $5 billion in second U.S. assembly plant -document
RE
07/29TREVOR MILTON : U.S. charges Nikola founder Trevor Milton with lying to investors
RE
07/22RYAN COHEN : Flush from Reddit rally, GameStop plots store revival
RE
More news


© 2021 People and Ownership :   
John Tsai : Connections 


Latest news about John Tsai 
06/11PRESS RELEASE : Novartis investigational oral therapy iptacopan (LNP023) shows benefit as monotherapy in treatment-naïve patients with rare and life-threatening blood disorder paroxysmal nocturnal hemoglobinuria
DJ
06/07NOVARTIS' : Iptacopan Trial in Rare Kidney Disease Meets Primary Endpoint
MT
06/06PRESS RELEASE : Novartis announces iptacopan met Phase II study primary endpoint in rare kidney disease IgA nephropathy (IgAN)
DJ
06/03PRESS RELEASE : Novartis reports clinically relevant improvement in median overall survival data in final analysis of pivotal NETTER-1 study with targeted radioligand therapy Lutathera
DJ
06/03NOVARTIS' : nuclear therapy helps men with prostate cancer live longer - data
RE
06/03PRESS RELEASE : Novartis 177Lu-PSMA-617 significantly improves overall survival and radiographic progression-free survival for men with metastatic castration-resistant prostate cancer in Phase III VISION study
DJ
05/28PRESS RELEASE : Novartis reports one year results of Phase III MERLIN study evaluating Beovu(R) every four week dosing and provides update on Beovu clinical program
DJ
More news